Last reviewed 2026-05-14 · How we verify

HCP1701

HCP1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.

HCP1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

HCP1701 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion while simultaneously suppressing glucagon release. The extended half-life formulation allows for less frequent dosing while maintaining sustained metabolic effects on blood glucose regulation.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Gastrointestinal disorders

Key clinical trials

• A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia (PHASE3)
• A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HCP1701 CI brief — competitive landscape report
• HCP1701 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI